News
GTBP
2.350
+0.86%
0.020
Weekly Report: what happened at GTBP last week (0324-0328)?
Weekly Report · 6d ago
Weekly Report: what happened at GTBP last week (0317-0321)?
Weekly Report · 03/24 12:09
Weekly Report: what happened at GTBP last week (0310-0314)?
Weekly Report · 03/17 12:24
Weekly Report: what happened at GTBP last week (0303-0307)?
Weekly Report · 03/10 12:26
GT Biopharma files to sell 625,283 shares of common stock for holders
TipRanks · 03/06 22:25
GT Biopharma's Dr. Jeffrey Miller to Present on Tri-Specific Killer Engagers at Innate Killer Summit
NASDAQ · 03/04 12:12
Weekly Report: what happened at GTBP last week (0224-0228)?
Weekly Report · 03/03 12:25
GT Biopharma Retail Chatter Soars Most Among Biotechs After Financing Strategy Tweak
Barchart · 02/25 21:00
GT Biopharma could report Phase 1 trial data later this year, says Roth MKM
TipRanks · 02/25 17:40
GT Biopharma Announces Exercise of Warrants
Barchart · 02/25 13:00
GT BIOPHARMA ANNOUNCES REQUEST FOR WITHDRAWAL OF FORM S-1 REGISTRATION STATEMENT
Reuters · 02/25 12:00
Weekly Report: what happened at GTBP last week (0217-0221)?
Weekly Report · 02/24 12:25
Based on the provided financial report articles, I generated the title for the article: "GTBP's 2024 Financial Report: A Comprehensive Overview of the Company's Financial Performance and Position" Please note that the title may not be exact, as the provided text does not contain a clear title. However, based on the content, I attempted to create a title that summarizes the main topic of the article.
Press release · 02/21 23:36
Weekly Report: what happened at GTBP last week (0210-0214)?
Weekly Report · 02/17 12:21
Weekly Report: what happened at GTBP last week (0203-0207)?
Weekly Report · 02/10 12:12
Weekly Report: what happened at GTBP last week (0127-0131)?
Weekly Report · 02/03 12:19
GT Biopharma Doses First Patient In Phase 1 Trial Of GTB-3650 For Hematologic Malignancies
NASDAQ · 01/27 14:33
Weekly Report: what happened at GTBP last week (0120-0124)?
Weekly Report · 01/27 12:23
GT Biopharma announces first patient dosed in Phase 1 trial of GTB-3650
TipRanks · 01/27 12:12
GT Biopharma Doses Initial Patient In Phase 1 Trial Of GTB-3650, Next-Generation TriKE For Hematologic Cancer Treatment
Benzinga · 01/27 12:09
More
Webull provides a variety of real-time GTBP stock news. You can receive the latest news about Gt Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About GTBP
More
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.